STOCK TITAN

Amgen (NASDAQ: AMGN) SVP receives 3,266 options and 500-share award

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amgen Inc. senior vice president Rachna Khosla reported routine equity compensation changes. On May 5, 2026, she received an award of 500 shares of common stock at $0.00 per share and a grant of 3,266 non-qualified stock options with a $329.59 exercise price, all under Amgen’s Equity Incentive Plan. The options and related Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027. On May 6, 2026, 79 shares of common stock at $329.59 were withheld to cover tax obligations. After these transactions, she directly holds 8,487 shares of Amgen common stock.

Positive

  • None.

Negative

  • None.
Insider Khosla Rachna
Role SVP, Business Development
Type Security Shares Price Value
Tax Withholding Common Stock 79 $329.59 $26K
Grant/Award Nqso (Right to Buy) 3,266 $329.59 $1.08M
Grant/Award Common Stock 500 $0.00 --
Holdings After Transaction: Common Stock — 8,487 shares (Direct, null); Nqso (Right to Buy) — 3,266 shares (Direct, null)
Footnotes (1)
  1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
Tax-withholding shares 79 shares Shares withheld at $329.59 on May 6, 2026
Tax-withholding price $329.59/share Price for 79 withheld shares on May 6, 2026
Post-transaction holdings 8,487 shares Direct Amgen common stock after reported transactions
Stock award 500 shares Common stock grant on May 5, 2026 at $0.00
Option grant size 3,266 options Non-qualified stock options granted May 5, 2026
Option exercise price $329.59/share Exercise price for 3,266 non-qualified stock options
Option expiration May 5, 2036 Expiration date of non-qualified stock options
Vesting schedule start May 5, 2027 RSUs and options vest 25% annually from this date
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Dividend Equivalents (DEs) financial
"These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan"
non-qualified stock options financial
"These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan)"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khosla Rachna

(Last)(First)(Middle)
ONE AMGEN CENTER DRIVE

(Street)
THOUSAND OAKS CALIFORNIA 91320

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, Business Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A500(1)A$08,566D
Common Stock05/06/2026F79D$329.598,487(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Nqso (Right to Buy)$329.5905/05/2026A3,26605/05/2027(3)05/05/2036Common Stock3,266$329.593,266D
Explanation of Responses:
1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
/s/ Rachna Khosla05/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Amgen (AMGN) SVP Rachna Khosla report on this Form 4?

Amgen SVP Rachna Khosla reported routine equity compensation activity, including a grant of 500 shares of common stock, 3,266 non-qualified stock options, and 79 shares withheld to cover taxes. All transactions relate to Amgen’s equity incentive compensation program.

How many Amgen (AMGN) shares does Rachna Khosla hold after these transactions?

After these transactions, Rachna Khosla directly holds 8,487 shares of Amgen common stock. This figure reflects her position following the equity grants and the 79-share tax-withholding disposition reported in the filing.

What equity awards did Amgen (AMGN) grant to Rachna Khosla in this filing?

Amgen granted Rachna Khosla 500 shares of common stock and 3,266 non-qualified stock options with a $329.59 exercise price. The awards were issued under Amgen’s Equity Incentive Plan as part of her ongoing compensation.

What are the vesting terms for Rachna Khosla’s Amgen (AMGN) RSUs and options?

The Restricted Stock Units and related non-qualified stock options vest in four equal annual installments of 25% each, starting May 5, 2027. Vested RSUs are settled in Amgen common stock on a one-to-one basis according to this schedule.

Why were 79 Amgen (AMGN) shares disposed of in this Form 4?

The 79-share disposition was a tax-withholding event, not an open-market sale. Shares were withheld at $329.59 per share to satisfy tax obligations associated with Khosla’s equity compensation awards under the company’s plan.

What does the 3,266-share non-qualified stock option grant mean for Amgen (AMGN) SVP Khosla?

The 3,266 non-qualified stock options give Khosla the right to buy Amgen common shares at $329.59 until May 5, 2036. These options vest in four annual 25% installments beginning May 5, 2027, subject to the plan’s terms.